biologics

More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...

Bertis, South Korean company specializing in the development of proteomics-based precision medicine technology, announced on Monday that it presente...

Samsung Group leader Lee Jae-yong, currently in the US, has vowed to make biotechnology the conglomerate’s second core strategic business afte...

South Korea’s Lotte Biologics Co. said on Friday that it has made an equity investment in Pinotbio, Inc. for the development of antibody-drug ...

South Korea’s Lotte Biologics Co. held a plaque ceremony on Monday to commemorate the acquisition of a pharmaceutical production plant from Br...

Lotte Biologics, South Korea's biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Sunday that it has...

Samsung Biologics Co. is slated to inject 2 trillion won ($1.5 billion) to build its fifth plant in South Korea. It will be a fast follow-up investm...

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday th...

Samsung Biologics Co., the world’s No. 1 contract drug maker in terms of production capacity, has won a $182.7 million contract manufacturing ...

Samsung Biologics Co., the world’s top contract drugmaker, said its profit almost doubled last year thanks to more orders as its sales surged ...

John Rim, chief executive of Samsung BioLogics will directly lead his company's global sales operations for biopharmaceuticals through contract deve...

SAN FRANCISCO -- South Korea’s Lotte Biologics Co. is considering investing more in the US bio industry and spending $3 billion in new factori...

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it was awarded the Sustainable Markets Initiative’s Ter...

Hansol Chemical Co., a unit of South Korea’s paper-focused conglomerate Hansol Group, is expanding its business scope to biomaterials by acqui...

FRANKFURT – Samsung Biologics Co., the world’s largest contract drugmaker, is in talks to develop medicines for a global pharmaceutical ...

South Korea’s Samsung Biologics Co. has signed a $296.1 million deal to supply biopharmaceutical products to UK-based multinational pharma gia...

South Korea’s Samsung Biologics Co.’s new biopharmaceuticals plant launched operations on Tuesday, a move expected to widen the gap betw...

The Life Science Fund, jointly launched by Samsung Biologics and Samsung C&T Corp., announced Wednesday it invested $15 million in US biotech fi...

Samsung Biologics Co., the world’s largest contract drugmaker, plans to double its manufacturing capacity by building four additional plants w...

South Korea’s two major biopharmaceutical companies, Celltrion Inc. and Samsung Biologics Co., are respectively expecting more than 2 trillion...

South Korea’s Samsung Biologics Co. has inked an $81 million contract manufacturing deal with Novartis, the world’s fifth-largest pharma...

South Korea's Lotte Group has agreed to buy Bristol Myers Squibb's (BMS) biologics plant in Syracuse in the state of New York for $160 million, the ...

South Korea’s pharmaceutical company Kolon Life Science Inc. signed a technology export deal worth up to 723.4 billion won ($589.1 million) wi...

Samsung Biologics Co., a global contract development and manufacturing organization (CDMO) and a biotech division under the Samsung Group, is set ...

South Korea approved exports of Moderna Inc.’s COVID-19 vaccine produced by Samsung Biologics Co. in a move that will help the country’s...

Samsung Biologics Co., a global contract development and manufacturing organization (CDMO), has stepped up its partnerships with global big pharmas ...

Moderna Inc.’s COVID-19 vaccine first produced by Samsung Biologics Co. under a contract manufacturing organization (CMO) service will be avai...

South Korea’s Samsung Biologics Co. is gearing up for the drug substance (DS) sector of the messenger ribonucleic acid (mRNA)-based COVID-19 v...

The South Korean government will invest 2.2 trillion won ($1.9 billion) by 2025 to become a top five vaccine producer in the world. President Moon J...

South Korean biosimilar companies such as Celltrion Inc. and Samsung Bioepis Co. are likely to see their sales hike by tens of millions of dollars...